Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues.

On the contrary, in the large nonrandomized registry, the Coronary Revascularization Demonstrating Outcome (CREDO)-Kyoto Registry Cohort-2 [ 43 ], prolonged thienopyridine therapy beyond 1 year did not reduce ischemic events, but showed a trend toward increased bleeding.

also in 53,322 other papers